2020
Consolidation Therapy in Primary Central Nervous System Lymphoma
Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyCentral nervous system lymphomaLong-term remissionNervous system lymphomaConsolidation therapyInduction therapyPerformance statusTransplant candidatesSystem lymphomaOpinion statementPrimary central nervous system lymphomaPrimary central nervous system lymphomaAutologous stem cell transplantTransplant-related mortality riskAdequate organ functionFavorable performance statusInitial induction therapyECOG performance statusHigh-dose cytarabineHigh-dose methotrexateHigh-dose chemotherapyStem cell transplantEnd of inductionHigh response rateCurative intentMyeloablative regimenCerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesCSF cytologyCSF CTCsCTC enumerationCerebrospinal fluidIT trastuzumabPhase I/II dose escalation trialCentral nervous system compartmentTumor cellsHER2/neu positivityHER2/neu expressionDose-escalation trialHER2-positive cancersIntrathecal trastuzumabEscalation trialRadiographic responseTumor burdenPositive cancersNeu expressionNeu positivityConclusionOur studyPatientsDay 1Epithelial cancersCancer
2019
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal Of Neuro-Oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCognitionCombined Modality TherapyCranial IrradiationFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLongitudinal StudiesLymphomaMaleMiddle AgedPrognosisQuality of LifeSurvival RateTransplantation, AutologousYoung AdultConceptsWhole brain radiotherapyReduced-dose whole-brain radiotherapyPrimary central nervous system lymphomaHDC-ASCTCortical atrophyAttention/executive functionPCNSL patientsAutologous stem cell transplantConsolidation whole-brain radiotherapyAutologous stem cell transplantationCentral nervous system lymphomaCognitive functionIntroductionThe standard treatmentLongitudinal cognitive assessmentsProgression-free patientsHigh-dose chemotherapyMethotrexate-based chemotherapyLong-term remissionPrimary CNS lymphomaNervous system lymphomaStem cell transplantStem cell transplantationBrain structure abnormalitiesPost-induction chemotherapyWhite matter disease
2017
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology 2017, 20: 674-686. PMID: 29106665, PMCID: PMC5892140, DOI: 10.1093/neuonc/nox208.Peer-Reviewed Original ResearchConceptsAdverse eventsRecurrent glioblastomaCommon treatment-related adverse eventsTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionEffects of nivolumabExploratory efficacy outcomesSafety/tolerabilityFindings merit further investigationLigand 1 expressionCheckMate 143Ipilimumab doseNivolumab monotherapyStable diseaseAlternative regimenEfficacy outcomesRadiographic progressionMost patientsPartial responseNivolumabIpilimumabMerit further investigationPatientsI cohortFurther evaluation
2016
Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology 2016, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaProgression-free survivalOverall survivalCNS lymphomaPrognostic valueMRI characteristicsRandomized phase II trialEarly MRI evaluationFirst-line chemotherapyPatterns of relapsePhase II trialBaseline tumor sizeEnd of treatmentOverall tumor burdenPotential prognostic valueComplete response achievementHypersignal lesionsInfratentorial localizationProlonged OSII trialObjective responsePoor OSProspective trialMRI abnormalitiesTumor burdenLong-term survival in AIDS-related primary central nervous system lymphoma
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology 2016, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyWhole brain radiotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaAR-PCNSLNervous system lymphomaHD-MTXLong-term survivalMulticenter analysisSystem lymphomaAdvent of cARTLong-term disease-free survivalLonger progression-free survivalSan Francisco General HospitalHigh-dose methotrexateDisease-free survivalProgression-free survivalOptimal therapeutic approachTherapy-related factorsFirst-line interventionPost-cART eraLong-term toxicityAntiretroviral therapyBrain radiotherapyFavorable survivalSecond‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care
Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-2714. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDiagnostic ErrorsFemaleFollow-Up StudiesHumansImage Interpretation, Computer-AssistedInfantMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeoplasmsNeuroimagingObserver VariationPatient CarePhysiciansPrognosisRadiologistsReferral and ConsultationRetrospective StudiesTomography, X-Ray ComputedYoung AdultConceptsSecond-opinion interpretationsPatient managementMagnetic resonance imaging studySecond-opinion radiology reportsResonance imaging studyNational Cancer InstitutePatient ageNeuro-oncologistsCancer CenterDisease stageStudy criteriaCancer patientsClinical assessmentClinical impactNeck surgeonsRetrospective analysisHistopathologic analysisCancer InstituteImaging studiesRadiology reportsOutside reportsReference standardNeuroradiologistsSurgeonsDiscrepant reports
2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology 2015, 18: 283-290. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.Peer-Reviewed Original ResearchConceptsTumor volumeDisease monitoringIsocitrate dehydrogenase (IDH) mutant gliomasProton magnetic resonance spectroscopyConsecutive glioma patientsMR imaging protocolMagnetic resonance spectroscopyCytoreductive therapyTumor levelsLarge tumorsTumor gradeSmall tumorsGlioma patientsGlioma imagingGlioma therapyClinical practiceClinical implicationsRoutine MRTumor cellularityTumor cellsIDH-mutant gliomasGliomasMetabolite RImaging protocolMitotic indexOrally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology 2015, 18: 557-564. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAminopyridinesBiomarkers, TumorBlood-Brain BarrierBrain NeoplasmsCohort StudiesFemaleFollow-Up StudiesGlioblastomaHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPyrrolesReceptors, Granulocyte-Macrophage Colony-Stimulating FactorTissue DistributionTumor BurdenConceptsPhase II studyII studyRecurrent glioblastomaTumor tissueMedian drug levelsPrimary efficacy endpointProgression-free survivalBlood-brain barrierPretreatment baseline valuesBlood-tumor barrierExploratory endpointsInhibitor PLX3397Efficacy endpointPrimary endpointSecondary endpointsObjective responseSurgical resectionOral dosePharmacodynamic changesPharmacodynamic measuresTumor burdenDrug exposureTissue pharmacokineticsDrug levelsStem cell factorFirst-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factorsR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-1410. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideCytarabineFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNeoplasm GradingNeoplasm StagingProcarbazinePrognosisRituximabSurvival RateThiotepaTransplantation, AutologousVincristineYoung AdultConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyPrimary central nervous system lymphomaStem cell transplantOverall survivalR-MPVHigh-dose methotrexate-based chemotherapyTwo-year progression-free survivalConsolidation high-dose chemotherapyMedian progression-free survivalCentral nervous system lymphomaMedian Karnofsky performance status 80Treatment-related deathsTwo-year OSCycles of chemotherapyMethotrexate-based chemotherapyObjective response ratePrimary end pointAcceptable toxicity profileMainstay of treatmentPhase 2 studyPrimary CNS lymphomaNervous system lymphomaBlood-brain barrier
2014
Current Role of Anti-Angiogenic Strategies for Glioblastoma
Thomas AA, Omuro A. Current Role of Anti-Angiogenic Strategies for Glioblastoma. Current Treatment Options In Oncology 2014, 15: 551-566. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase III trialsIII trialsOverall survivalRecurrent diseaseStandard chemoradiotherapyClinical benefitAnti-vascular endothelial growth factor monoclonal antibodyCognitive declineSimilar progression-free survivalToxicity of bevacizumabAddition of bevacizumabPhase II trialSevere neurologic symptomsFactor monoclonal antibodyNew drug combinationsAnti-angiogenic therapyReduced vascular permeabilityQuality of lifeUnquestionable clinical benefitObserved cognitive declineBevacizumab armOS trendsCorticosteroid useFree survivalAutologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide
Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leukemia & Lymphoma 2014, 56: 361-367. PMID: 24745937, DOI: 10.3109/10428194.2014.916800.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideDisease-Free SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRemission InductionStem Cell TransplantationThiotepaTransplantation, AutologousTreatment OutcomeConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyStem cell transplantOverall survivalCell transplantSecondary central nervous system lymphomaRefractory diffuse large B-cell lymphomaMedian progression-free survivalCentral nervous system involvementCentral nervous system lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaTransplant-related mortalityNervous system involvementSecondary CNS lymphomaNervous system lymphomaStem cell harvestingB-cell lymphomaPotential treatment alternativeHDC-ASCTInduction chemotherapyRecurrent primaryCNS lymphomaComplete remissionTranscriptional diversity of long-term glioblastoma survivors
Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology 2014, 16: 1186-1195. PMID: 24662514, PMCID: PMC4136896, DOI: 10.1093/neuonc/nou043.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterLong-term survivorsLong-term glioblastoma survivorsIDH mutationsIDH2 mutational statusMedian overall survivalStrong prognostic valueBiology of glioblastomaMGMT promoter methylationMedian survivalOverall survivalBetter prognosisPoor prognosisPrognostic valueCancer CenterAggressive typeIndependent cohortMesenchymal subtypeREMBRANDT cohortMutational statusIDH2 mutationsGBM biologyPatientsMGMT methylationMGMT promoterMethotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2013
Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma
Young R, Gupta A, Shah A, Graber J, Schweitzer A, Prager A, Shi W, Zhang Z, Huse J, Omuro A. Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma. American Journal Of Neuroradiology 2013, 34: 2271-2277. PMID: 23811973, PMCID: PMC4712068, DOI: 10.3174/ajnr.a3604.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsErbB ReceptorsFemaleGene AmplificationGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedMolecular ImagingPreoperative CarePrognosisReproducibility of ResultsSensitivity and SpecificityTissue DistributionUp-RegulationYoung Adult
2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology 2012, 15: 242-250. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreProgression-free survival ratesBevacizumab-naive patientsRecurrent malignant gliomaPhase II trialMalignant gliomasII trialPrimary endpointSurvival rateContinuous low-dose temozolomideMedian Karnofsky performance scoreLow Karnofsky performance scoreAdvanced malignant gliomaLow-dose temozolomideMedian overall survivalHalf of patientsFurther treatment strategiesMutations of EGFRBevacizumab exposureEligible patientsTemozolomide schedulesMG patientsOverall survivalMedian ageClinical benefitOutcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterOlder patientsCancer CenterSurvival rateLower baseline creatinine clearanceMedian progression-free survivalTwo-year survival rateBaseline creatinine clearanceDeep brain involvementSignificant renal toxicityMedian overall survivalPrimary CNS lymphomaProgression-free survivalTertiary care centerHigh-dose MTXPredictors of survivalFifth treatment cycleOcular radiationAggressive therapyCNS lymphomaBrain involvementCreatinine clearanceMost patientsOverall survivalPCNSL patientsLimited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.Peer-Reviewed Original ResearchConceptsBrain metastasesOverall survivalBreast cancerDiagnosis of BMIncidence of BMMedian age 53 yearsRisk of BMTriple-negative breast cancerActuarial median survivalLimited overall survivalAge 53 yearsGroup of patientsPatterns of recurrenceSingle-institution studyNegative breast cancerElectronic medical recordsBM diagnosisMedian survivalMetastatic diseaseEntire cohortRetrospective studyTherapeutic optionsInstitutional databaseMedical recordsModern therapyAtypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumors